McCullough Robertson’s Equity Capital Markets and Life Sciences team has successfully assisted Imugene Limited in raising up to $146 million – $80 million Institutional Placement with up to $66 million in attaching options – to provide an extended runway for Imugene’s deep pipeline of clinical programmes.

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Imugene is passionate about bringing innovative and effective new treatments and options to patients, and have a large portfolio of current clinical trials and pipelines.

The McCullough Robertson team, led by Partner Reece Walker, has proudly worked with Imugene since 2013.